At present, biomarkers including PD⁃L1, tumor mutational burden (TMB) and mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) have shown some predictive value, and are approved by the FDA and/or the NMPA as indicators for predicting the efficacy of immunotherapy in NSCLC or other solid tumors. The gene discussed is CD274; the disease is non-small cell lung carcinoma.